心肾综合征的诊治最新进展

摘要
图/表
参考文献(64)
相关文章 (15)

全文: PDF (616 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

心肾综合征（CRS）是指心脏和肾脏同时出现急性或慢性功能障碍，导致一系列连锁反应，并对心脏和肾脏造成互损，具有较高的发病率和死亡率。当前临床上CRS 主要包括5 种类型，不同的CRS 致病机制不同，且表型之间存在很大差异。尽管近年来心力衰竭（HF）和慢性肾脏病（CKD）的基础研究和综合管理手段取得了较大进展，但在CRS 中具有里程碑意义的代表性随机对照研究不足，而且这些患者的治疗主要是从相应的HF 或CKD试验中推断出来的，因此，目前仍无非常有效的针对CRS 的治疗措施。随着医疗卫生技术和人口老龄化的进展，CRS 越来越受到人们的重视，根据最新研究结果对CRS 患者进行最佳评估管理愈显重要。本文复习总结当前国内外最新研究成果，就CRS 的诊断、发病机制、临床治疗等最新进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	翟秋月
	刘文花

关键词 ：心肾综合征, 心力衰竭, 急性肾损伤, 慢性肾脏病

Abstract：

Cardiorenal syndrome(CRS)refers to the simultaneous acute or chronic dysfunction of the heart and kidney,resulting in a series of chain reactions and mutual damage to the heart and kidneys,with high morbidity and mortality.Currently,there are mainly 5 types of CRS in clinical practice,and different CRS have different pathogenic mechanisms and great differences in phenotypes.Despite significant advances in basic research and integrated management of heart failure(HF)and chronic kidney disease (CKD)in recent years,representative randomized controlled landmark studies in CRS are insufficient,and the treatment of these patients is mainly inferred from the corresponding HF or CKD trials.There is no effective treatment for CRS.With the advancement of healthcare technology and aging population,CRS has received increasing attention,and it is increasingly important to conduct the best assessment and management of CRS patients according to the latest research results.This article reviews the latest research results at home and abroad,and reviews the latest progress in the diagnosis,pathogenesis and clinical treatment of CRS.

Key words： Cardiorenal syndrome Heart failure Acute kidney injury Chronic kidney disease

通讯作者: 刘文花（1977-），女，青海西宁人，教授，主任医师，硕士生导师，青海省人民医院肾内科主任，研究方向：肾脏病。

作者简介: 翟秋月（1991-），女，陕西汉中人，青海大学2022 级内科学在读硕士研究生；研究方向：肾脏病。

引用本文:

翟秋月；刘文花. 心肾综合征的诊治最新进展[J]. 中国当代医药, 2024, 31(14): 186-191.
ZHAI Qiuyue； LIU Wenhua . Latest progress in the diagnosis and treatment of cardiorenal syndrome. 中国当代医药, 2024, 31(14): 186-191.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2024/V31/I14/186

[1]	Kim JA，Wu L，Rodriguez M，et al.Recent developments in the evaluation and management of cardiorenal syndrome：a comprehensive review[J].Curr Probl Cardiol，2023，48（3）：101509.
[2]	Lewis T.A Clinical lecture on paroxysmal dyspenoea in cardiorenal patients：with special reference to“cardiac”and“uraemic”asthma：delievered at university college hospital，London，November 12th 1913[J].Br Med J，1913，2（2761）：1417-1420.
[3]	Haase M，Müller C，Damman K，et al.Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure：workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative（ADQI）[J].Contrib Nephrol，2013（182）：99-116.
[4]	Rangaswami J，Bhalla V，Blair JEA，et al.Cardiorenal syndrome：classification，pathophysiology，diagnosis，and treatment strategies：a scientific statement from the American Heart Association[J].Circulation，2019，139（16）：e840-e878.
[5]	Jentzer JC，Bihorac A，Brusca SB，et al.Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome：JACC council perspectives[J].J Am Coll Cardiol，2020，76（9）：1084-1101.
[6]	Ronco C，Haapio M，House AA，et al.Cardiorenal syndrome[J].J Am Coll Cardiol，2008，52（19）：1527-1539.
[7]	Hatamizadeh P，Fonarow GC，Budoff MJ，et al.Cardiorenal syndrome：pathophysiology and potential targets for clinical management[J].Nat Rev Nephrol，2013，9（2）：99-111.
[8]	Forman DE，Butler J，Wang Y，et al.Incidence，predictors at admission，and impact of worsening renal function among patients hospitalized with heart failure[J].J Am Coll Cardiol，2004，43（1）：61-67.
[9]	Lorin J，Guilland JC，Stamboul K，et al.Increased symmetric dimethylarginine level is associated with worse hospital outcomes through altered left ventricular ejection fraction in patients with acute myocardial infarction[J].PloS One，2017，12（1）：e0169979.
[10]	Tharaux PL.Histamine provides an original vista on cardiorenal syndrome[J].Proc Natl Acad Sci U S A，2020，117（11）：5550-5552.
[11]	Susantitaphong P，Cruz DN，Cerda J，et al.World incidence of AKI：a meta-analysis[J].Clin J Am Soc Nephrol，2013，8（9）：1482-1493.
[12]	Cowie MR，Komajda M，Murray-Thomas T，et al.Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure：results of the prospective outcomes study in heart failure（POSH）[J].Eur Heart J，2006，27（10）：1216-1222.
[13]	Herzog CA.Congestive heart failure and chronic kidney disease：the cardiorenal/nephrocardiology connection[J].J Am Coll Cardiol，2019，73（21）：2701-2704.
[14]	Bansal S，Prasad A，Linas S.Right heart failure-unrecognized cause of cardiorenal syndrome[J].J Am Soc Nephrol，2018，29（7）：1795-1798.
[15]	Tang M，Batty JA，Lin C，et al.Pulmonary hypertension，mortality，and cardiovascular disease in CKD and ESRD patients：a systematic review and meta-analysis[J].Am J Kidney Dis，2018，72（1）：75-83.
[16]	Méndez AB，Azancot MA，Olivella A，et al.New aspects in cardiorenal syndrome and HFpEF[J].Clin Kidney J，2022，15（10）：1807-1815.
[17]	Thind GS，Loehrke M，Wilt JL.Acute cardiorenal syndrome：mechanisms and clinical implications[J].Cleve Clin J Med，2018，85（3）：231-239.
[18]	Jia G，Aroor AR，Hill MA，et al.Role of renin-angiotensinaldosterone system activation in promoting cardiovascular fibrosis and stiffness[J].Hypertension，2018，72（3）：537-548.
[19]	Halade GV，Lee DH.Inflammation and resolution signaling in cardiac repair and heart failure[J].EBioMedicine，2022，791 03992.
[20]	Everett BM，Macfadyen JG，Thuren T，et al.Inhibition of interleukin-1beta and reduction in atherothrombotic cardiovascular events in the CANTOS trial[J].J Am Coll Cardiol，2020，76（14）：1660-1670.
[21]	Sung PH，Chai HT，Yang CC，et al.Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat[J].Biomed Pharmacother，2022，148：112745.
[22]	Virzì GM，Zhang J，Nalesso F，et al.The role of dendritic and endothelial cells in cardiorenal syndrome[J].Cardiorenal Med，2018，8（2）：92-104.
[23]	Wang J，Zhu P，Li R，et al.Bax inhibitor 1 preserves mitochondrial homeostasis in acute kidney injury through promoting mitochondrial retention of PHB2[J].Theranostics，2020，10（1）：384-397.
[24]	Wang J，Zhu P，Li R，et al.Fundc1-dependent mitophagy is obligatory to ischemic preconditioning-conferred renoprotection in ischemic AKI via suppression of Drp1-mediated mitochondrial fission[J].Redox Biol，2020，30：101415.
[25]	Sumida M，Doi K，Ogasawara E，et al.Regulation of mitochondrial dynamics by dynamin-related protein-1 in acute cardiorenal syndrome[J].J Am Soc Nephrol，2015，26（10）：2378-2387.
[26]	Ishrat R，Ahmed MM，Tazyeen S，et al.In silico integrative approach revealed key microRNAs and associated target genes in cardiorenal syndrome[J].Bioinform Biol Insights，2021，15：11779322211027396.
[27]	Di J，Yang M，Zhou H，et al.MicroRNA-21-containing microvesicles from tubular epithelial cells promote cardiomyocyte hypertrophy[J].Ren Fail，2021，43（1）：391-400.
[28]	Gembillo G，Visconti L，Giusti M A，et al.Cardiorenal syndrome：new pathways and novel biomarkers[J].Biomolecules，2021，11（11）：1581.
[29]	Huang CK，C，Thum T.miR-21，Mediator，and potential therapeutic target in the cardiorenal syndrome[J].Front Pharmacol，2020，11：726.
[30]	Patel N，Yaqoob MM，Aksentijevic D.Cardiac metabolic remodellingin chronic kidney disease[J].Nat Rev Nephrol，2022，18（8）：524-537.
[31]	Patel KP，Katsurada K，Zheng H.Cardiorenal syndrome：the role of neural connections between the heart and the kidneys[J].Circ Res，2022，130（10）：1601-1617.
[32]	Gallo G，Lanza O，Savoia C.New insight in cardiorenal syndrome：from biomarkers to therapy[J].Int J Mol Sci，2023，24（6）：5089.
[33]	Matsui M，Onoue K，Saito Y.sFlt-1 in chronic kidney disease：friend or foe?[J].Int J Mol Sci，2022，23（22）：14187.
[34]	Takahama H，Nishikimi T，Takashio S，et al.Change in the NT-proBNP/mature BNP molar ratio Precedes worsening renal function in patients with acute heart failure：a novel predictor candidate for cardiorenal syndrome[J].J Am Heart Assoc，2019，8（17）：e011468.
[35]	Yancy CW，Jessup M，Bozkurt B，et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J].J Card Fail，2017，23（8）：628-651.
[36]	Ng LL，Squire IB，Jones DJL，et al.Proenkephalin，renal dysfunction，and prognosis in patients with acute heart failure：a GREAT network study[J].J Am Coll Cardiol，2017，69（1）：56-69.
[37]	J，de La Espriella R，Minana G，et al.Antigen carbohydrate 125 as a biomarker in heart failure：a narrative review[J].Eur J Heart Fail，2021，23（9）：1445-1457.
[38]	Lena A，Anker MS，Springer J.Muscle wasting and sarcopenia in heart failure-the current state of science[J].Int J Mol Sci，2020，21（18）：6549.
[39]	Yamamoto R，Imai E，Maruyama S，et al.Acute kidney injury and remission of proteinuria in minimal change disease[J].Kidney Int Rep，2022，7（10）：2283-2288.
[40]	G，Llàcer P，Sanchis I，et al.Early spot urinary sodium and diuretic efficiency in acute heart failure and concomitant renal dysfunction[J].Cardiorenal Med，2020，10（5）：362-372.
[41]	Martens P，Dupont M，Verbrugge FH，et al.Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure[J].JACC Heart Fail，2019，7（5）：404-414.
[42]	郭茂松，王群文，尹路.肾脏血流动力学超声监测对急性肾损伤的预测价值[J].临床急诊杂志，2023，24（9）：454-459.
[43]	金亮丽，王治.现代医学影像学在心肾综合征中的应用进展[J].心血管病学进展，2021，42（7）：645-648.
[44]	Kuriyama A，Urushidani S.Continuous versus intermittent administration of furosemide in acute decompensated heart failure：a systematic review and meta-analysis[J].Heart Fail Rev，2019，24（1）：31-39.
[45]	Han B，Li H，Ma Q.Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension[J].Pak J Pharm Sci，2017，30（4（Suppl.）：1449-1453.
[46]	Lannemyr L，Ricksten SE，Rundqvist B，et al.Differential dffects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment：a randomized double-blind controlled trial[J].J Am Heart Assoc，2018，7（16）：e008455.
[47]	Heidenreich PA，Bozkurt B，Aguilar D，et al.2022 AHA/ACC/HFSA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].J Am Coll Cardiol，2022，79（17）：e263-e421.
[48]	Edner M，Benson LU，et al.Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency：a prospective propensity score-matched cohort study[J].Eur Heart J，2015，36（34）：2318-2326.
[49]	Weir MR，Lakkis JI，Jaar B，et al.Use of renin-angiotensin system blockade in advanced CKD：an NKF-KDOQI controversies report[J].Am J Kidney Dis，2018，72（6）：873-884.
[50]	Yeoh SE，Dewan P，Serenelli M，et al.Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES[J].Eur J Heart Fail，2022，24（3）：529-538.
[51]	Cheng S，Zhou T，Yu L，et al.The effect of Sacubitril/Valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 and stage 5 CKD after more than three years of follow-up[J].Front Med（Lausanne），2022，9：817833.
[52]	杨仲煌，邹贺，高美娟，等.血管紧张素受体脑啡肽酶抑制剂对心肾综合征患者肾功能影响[J].全科医学临床与教育，2022，20（6）：561-563.
[53]	Cice G，Calo' L，Monzo L.Sodium-glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome[J].Eur Heart J Suppl，2022，24（Suppl I）：I68-I71.
[54]	中华医学会糖尿病学分会，中华医学会内分泌学分会.中国成人2 型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J].中华内分泌代谢杂志，2020，36（6）：458-468.
[55]	《改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议》工作组.改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J].中国循环杂志，2020，35（3）：231-238.
[56]	Salvatore T，Galiero R，Caturano A，et al.An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors[J].Int J Mol Sci，2022，23（7）：3651.
[57]	闫康佳，张立晶，李蒙，等.中医药治疗心肾综合征的用药规律分析[J].中西医结合心脑血管病杂志，2022，20（8）：1345-1351.
[58]	张玉明，徐臣年，唐赛男，等.积雪草苷对Ⅱ型心肾综合征小鼠肾脏保护作用及其机制[J].山西医科大学学报，2023，54（7）：972-979.
[59]	刘成帅，孔淼，查玉玲，等.济阴决渎强心方对心肾综合征模型大鼠水钠排泄的影响[J].中国中西医结合杂志，2023，43（11）：1343-1349.
[60]	韦雪兰，张薇，杨珣，等.黄芪甲苷对心肾综合征的保护作用研究进展[J].中国处方药，2023，21（4）：162-166.
[61]	徐霞，宋庆桥，吴华芹，等.中西医结合治疗心肾综合征的Meta 分析[J].中国中医急症，2022，31（1）：16-21.
[62]	Hothi DK.Managing heart failure in dialysis patients[J].Pediatr Nephrol，2021，36（8）：2531-2535.
[63]	Blumer V，Greene SJ，Sun JL，et al.Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome：from the CARRESS-HF trial[J].Eur J Heart Fail，2019，21（11）：1472-1476.
[64]	Wong B，Ravani P，Oliver MJ，et al.Comparison of patient survival between hemodialysis and peritoneal dialysis among patients eligible for both modalities[J].Am J Kidney Dis，2018，71（3）：344-351.